Latest News > Portfolio Company News

Great Point Partners-Owned Ephicacy Consulting Group Completes Acquisition of Advance Research Associates

Add-on bolsters Ephicacy’s biostatistics and data management capabilities

GREENWICH, Conn – May 2, 2024 – Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, today announced that its portfolio company, Ephicacy Consulting Group, Inc. (“Ephicacy”), completed its acquisition of Advance Research Associates (“ARA”), a provider of custom data management and biostatistical consulting services for clinical trials. The strategic acquisition enhances Ephicacy’s capabilities in the areas of biostatistics and data management, further strengthening the suite of solutions it offers to pharmaceutical, biotechnology, and medical device companies. Terms were not disclosed.

Since its founding in 2005, Ephicacy has grown into a leading biometrics Contract Research Organization (“CRO”) leveraging its global talent pool to deliver clinical analytics services. Ephicacy has a flexible service delivery approach offering both Functional Service Provider (“FSP”) and project-based solutions to its global client base.

As part of the transaction, ARA Founder and CEO Peter Shabe joins the Ephicacy team as Global Head of Biostatistics Consulting, along with a group of talented and experienced statisticians and data management experts from ARA.

“We are thrilled to welcome Peter and the rest of the talented ARA team to Ephicacy and to offer our clients the expertise that ARA has built over nearly three decades,” said Ganesh Gopal, CEO of Ephicacy. “Now, more than ever, drug developers need reliable partners who can help them navigate the complexities of data in clinical trials. This acquisition deepens our biostatistics and data management solutions and reinforces our ability to drive impactful outcomes for our clients and the patients they serve.”

Since its establishment in 1996, ARA has supported over 700 clinical trials by providing custom data management and biostatistical consulting services across pharmaceutical, biotech, medical device, and diagnostic companies.

“It is ARA’s mission to consistently provide the highest quality customized data management and biostatistical consulting services to our clients. Joining forces with Ephicacy represents a natural evolution of that mission,” said Peter Shabe, ARA Founder and Ephicacy’s incoming Global Head of Biostatistics Consulting. “Ephicacy shares our goals and core values, and I am eager to bring our collective expertise to the forefront of the health care industry.”

GPP completed a growth investment in Ephicacy in 2022, representing the firm’s sixth partnership with an IT-enabled health care services organization since its formation in 2003. Ephicacy recently announced four senior leadership appointments to further its position for continued growth.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages approximately $1.7B of capital (including committed and uncalled capital) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

About Ephicacy Consulting Group, Inc.

Headquartered in Iselin, NJ, with employees and operations across North America and India, Ephicacy is a rapidly growing biometrics CRO, providing outsourced statistical programming, biostatistics, data management, and real-world evidence analytics services to pharmaceutical and biotechnology companies. Since its founding in 2005, Ephicacy has established itself as a leading player in the clinical analytics space, leveraging a global talent pool to help global pharmaceutical and biotechnology companies reduce their time to market in a cost-effective manner. More information on the Company and its services can be viewed online at www.ephicacy.com.